Helen Louise Collins
CIK 1701247 · CHIEF MEDICAL OFFICER · last filed 2026-09-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
205 PARK ROAD
BURLINGAME, CA 94010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELVN | CHIEF MEDICAL OFFICER | 25,240 | $40.60 | $1.02M | -$808.1K | 3 | 2026-09-21 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | CHIEF MEDICAL OFFICER | 26,133 | $14.59 | $381.3K | -$5.11M | 14 | 2026-06-22 |
| KURA | Director | — | $9.76 | — | $0 | 6 | 2026-06-04 |
| IO Biotech, Inc. (IOBT) Delisted | Director | — | $0.05 | — | $0 | 3 | 2025-06-06 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | EVP and Chief Medical Officer | 69,547 | $38.00 | $2.64M | $0 | 9 | 2021-04-19 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | EVP and Chief Medical Officer | 44,298 | $178.75 | $7.92M | $0 | 14 | 2019-09-04 |
Recent Filings · Page 3 of 6
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-10 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-10-22 | Enliven Therapeutics, Inc. (IMRA) Delisted | Mixed | — | -$22.5K | EDGAR |
| 2024-10-18 | ELVN | Notice (144) | −25,000 | -$700.5K | EDGAR |
| 2024-06-07 | KURA | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | IO Biotech, Inc. (IOBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-15 | Enliven Therapeutics, Inc. (IMRA) Delisted | Mixed | — | -$451.9K | EDGAR |
| 2024-04-11 | ELVN | Notice (144) | −20,000 | -$396.4K | EDGAR |
| 2024-02-15 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | IO Biotech, Inc. (IOBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | KURA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.